← Back to archive How it works
Supported

Published fact-check

OpenAI Launches GPT-Rosalind for Life Sciences Research

Claim checked

“Super excited to launch GPT-Rosalind, our first frontier model built for scientific research across biology, drug discovery, and translational medicine.”

Published April 16, 2026 at 8:35 PM

Verdict

Supported

On April 16, 2026, OpenAI officially introduced GPT-Rosalind, a new frontier AI model specifically designed for scientific research in biology, drug discovery, and translational medicine. Named after the pioneering scientist Rosalind Franklin, the model is intended to assist researchers with hypothesis generation, experimental planning, and evidence synthesis. It is currently available as a research preview for qualified enterprise clients and through a specialized life sciences plugin for OpenAI's Codex platform.

5 reviewed sources behind this verdict.

Reasoning

The claim is directly supported by multiple news reports and official statements from April 16, 2026. Reports from Reuters (via CTV News and SRN News) confirm that OpenAI launched the model to deepen its presence in the life sciences sector. The model's capabilities in biochemistry, protein engineering, and genomics were highlighted in a press briefing and blog post. Furthermore, the reports identify major pharmaceutical and biotech partners, such as Amgen and Moderna, who are already integrating the model into their workflows.

Source quality: The evidence includes detailed reports from reputable news organizations (Reuters) citing official OpenAI blog posts and press briefings. The timing of the reports aligns perfectly with the current date and the social media announcement.

Key checks

  • Official Launch of GPT-Rosalind: OpenAI introduced GPT-Rosalind on Thursday, April 16, 2026, as a model with increased biology knowledge and scientific research capabilities.

  • Targeted Research Areas: The model is specifically built for biochemistry, drug discovery, genomics, and translational medicine, supporting tasks like experimental planning and hypothesis generation.

  • Availability and Partnerships: GPT-Rosalind is available as a research preview for qualified customers. OpenAI is collaborating with industry leaders including Amgen, Moderna, and Thermo Fisher Scientific.

Confidence

High